Menu
← Oncology Approval Tracker
FDA DECISION ·
Keytruda
pembrolizumab · Merck Sharp & Dohme
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line treatment of unresectable or metastatic colorectal cancer with high microsatellite instability or deficient mismatch repair.
LAMPGEN ANALYSIS
Why it matters
Moved checkpoint inhibition into first-line treatment for a molecularly defined colorectal cancer population.
What research teams should watch
Get mismatch-repair or MSI results before first-line treatment selection and reconcile discordant results.
PRIMARY RECORDS